Association of smoking with neurocognition, inflammatory and myeloid cell activation profiles in people with HIV on antiretroviral therapy

作者：Anjana Yadav, Gabrielle Gionet, Antoneta Karaj, Andrew V. Kossenkov, Toshitha Kannan, Mary Putt, Alisa J. Stephens Shields, Rebecca L. Ashare, Ronald G. Collman · 发表于：AIDS · 年份：2024 · DOI：10.1097/qad.0000000000004015 · 被引用次数：4 · 研究领域：HIV Research and Treatment、Tryptophan and brain disorders、Neuroinflammation and Neurodegeneration Mechanisms

OBJECTIVE: People with HIV (PWH) experience excess comorbidities, including neurocognitive disorders, which are linked to inflammation, particularly monocyte-macrophage activation. Smoking contributes to morbidity and mortality in well treated PWH. We investigated associations between smoking, neurocognitive function, and inflammation in PWH on antiretroviral therapy (ART). DESIGN: We used baseline data on cognition and inflammation from a longitudinal study of virologically suppressed PWH who do and do not smoke. METHODS: Participants completed four neurocognitive tests (seven measures), with a composite score as the primary measure. Inflammatory markers were plasma sCD14, sCD163, and CCL2/MCP-1; %CD14 + monocytes expressing CD16, CD163, and CCR2; and %CD8 + T cells co-expressing CD38/HLA-DR. Exploratory analyses included a plasma cytokine/chemokine panel, neurofilament light chain (NFL), hsCRP, and monocyte transcriptomes by RNAseq. RESULTS: We recruited 58 PWH [26 current smoking (PWH/S), 32 no current smoking (PWH/NS)]. Mean composite and individual neurocognitive scores did not differ significantly by smoking status except for the color shape task; PWH/S exhibited worse cognitive flexibility, with adjusted mean times 317.2 [95% confidence interval (CI) 1.4-632.9] ms longer than PWH/NS. PWH/S had higher plasma sCD14 than PWH/NS [median (IQR) 1820 (1678-2105) vs. 1551 (1284-1760) ng/ml, P = 0.009]. Other inflammatory markers were not significantly different between PWH/S a...